In Drosophila, genetic ablation of Lsp2 — a protein previously classified only as a larval storage protein but now identified as an adipose-tissue effector and feedback activator of mTORC1 — robustly extends lifespan without compromising reproduction or other key life-history traits. Lsp2 expression is induced by essential amino acids via mTORC1 and gated by broader nutrient-sufficiency signals. Its loss selectively reduces global translation of TOP (5'-terminal oligopyrimidine) mRNAs, which predominantly encode ribosomal proteins, in a 4E-BP-dependent manner — a mechanism mechanistically distinct from rapamycin's action on mTORC1.
This finding matters because it dissects a specific node in the mTORC1 longevity network that rapamycin — currently one of the most reproducible lifespan-extending interventions across species — cannot reach. Rapamycin resistance of TOP mRNA translation has been a persistent puzzle; Lsp2 fills that gap by acting as an amplifier of mTORC1 output selectively on this translational program. The lifespan extension without reproductive cost is notable, since most mTORC1 interventions involve trade-offs. Critically, this is Drosophila work, and Lsp2 itself has no direct mammalian ortholog, so translational relevance to humans is presently speculative. Whether analogous adipose-derived feedback activators regulate TOP mRNA translation and longevity in mammals is now the key open question. Incremental for practitioners today, but potentially paradigm-shifting for future drug targets upstream of rapamycin's blind spots.
